Mohanty Sanjay, Tsiouris Athanasios, Hammoud Zane
Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202, USA.
Metabolites. 2012 Nov 21;2(4):1004-11. doi: 10.3390/metabo2041004.
Glycosylation is among the most common post translation modifications of proteins in humans. Decades of research have demonstrated that aberrant glycosylation can lead to malignant degeneration. Glycoproteomic studies in the past several years have identified techniques that can successfully characterize a glycan or glycan profile associated with a high-grade dysplastic or malignant state. This review summarizes the current glycomic and glycoproteomic literature with specific reference to esophageal cancer. Esophageal adenocarcinoma represents a highly morbid and mortal cancer with a defined progression from metaplasia (Barrett's esophagus) to dysplasia to neoplasia. This disease is highlighted because (1) differences in glycan profiles between the stages of disease progression have been described in the glycoproteomic literature; (2) a glycan biomarker that identifies a given stage may be used as a predictor of disease progression and thus may have significant influence over clinical management; and (3) the differences in glycan profiles between disease and disease-free states in esophageal cancer are more dramatic than in other cancers.
糖基化是人类蛋白质最常见的翻译后修饰之一。数十年的研究表明，异常糖基化可导致恶性退变。过去几年的糖蛋白质组学研究已经确定了一些技术，这些技术能够成功地表征与高级别发育异常或恶性状态相关的聚糖或聚糖谱。本综述总结了当前糖组学和糖蛋白质组学文献，特别提及了食管癌。食管腺癌是一种高发病率和高死亡率的癌症，具有从化生（巴雷特食管）到发育异常再到肿瘤形成的明确进展过程。之所以强调这种疾病，是因为：（1）糖蛋白质组学文献中描述了疾病进展各阶段之间聚糖谱的差异；（2）识别特定阶段的聚糖生物标志物可作为疾病进展的预测指标，因此可能对临床管理产生重大影响；（3）食管癌疾病状态与无病状态之间的聚糖谱差异比其他癌症更为显著。
